Fibrosis in Patients with Chronic Hepatitis C: Detection and Significance

 

 Buy Article Permissions and Reprints

ABSTRACT

Estimates of the extent of hepatic fibrosis and the rate of fibrosis progression represent important surrogate end points for evaluation of the vulnerability of an individual patient and for assessment of the impact of treatment on natural history in chronic hepatitis C. Using the median fibrosis progression rate, the median expected time to cirrhosis in untreated patients is around 30 years. However, one third of patients have an expected median time to cirrhosis of less than 20 years and one third will only progress to cirrhosis in more than 50 years, if ever. Factors independently associated with fibrosis progression are duration of infection, age, male gender, consumption of alcohol, human immunodeficiency virus co-infection, and low CD4 count. Evaluation of fibrosis progression is useful to decide treatment. Among patients with sustained viral response, fibrosis regresses. Evaluation of fibrosis progression has permitted validation of the concept of suppressive therapy. Among patients without viral clearance, interferon alone or in combination with ribavirin significantly reduces fibrosis progression rate in comparison with progression before treatment and to control groups. There is a major need for noninvasive markers of liver fibrosis. None are clearly useful today for the diagnosis of early stages of fibrosis.

REFERENCES

• 1 WHO. Hepatitis C: global prevalence.  Wkly Epidemiol Rec . 1997;  72 341-344
  PubMedGoogle Scholar
• 2 Seeff L B, Buskell-Bales Z, Wright E C. Long-term mortality after transfusion-associated non-A non-B hepatitis.  N Engl J Med . 1992;  327 1906-1911
  CrossrefPubMedGoogle Scholar
• 3 Tong M J, el-Farra N S, Reikes A R, Co R L. Clinical outcomes after transfusion-associated hepatitis C.  N Engl J Med . 1995;  332 1463-1466
  CrossrefPubMedGoogle Scholar
• 4 Darby S C, Ewart D W, Giangrande P LF. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C.  Lancet . 1997;  350 1425-1431
  CrossrefPubMedGoogle Scholar
• 5 El-Serag H B, Mason A. Rising incidence of hepatocellular carcinoma in the United States.  N Engl J Med . 1999;  34 745-750
  PubMedGoogle Scholar
• 6 Taylor-Robinson S D, Foster G R, Arora S, Hargreaves S, Thomas H C. Increase in primary liver cancer in the UK, 1979-94 [letter].  Lancet . 1997;  350 1142-1143
  PubMedGoogle Scholar
• 7 Deuffic S, Poynard T, Buffat L, Valleron A-J. Trends in primary liver cancer [letter].  Lancet . 1998;  351 214-215
  PubMedGoogle Scholar
• 8 Deuffic S, Buffat L, Poynard T, Valleron A J. Modeling the hepatitis C virus epidemic in France.  Hepatology . 1999;  29 1596-1601
  CrossrefPubMedGoogle Scholar
• 9 Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C.  Lancet . 1997;  349 825-832
  CrossrefPubMedGoogle Scholar
• 10 Sobesky R, Mathurin P, Charlotte F. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view.  Gastroenterology . 1999;  116 378-386
  PubMedGoogle Scholar
• 11 Perrillo R P. The role of liver biopsy in hepatitis C.  Hepatology . 1997;  26 57S-61S
  CrossrefPubMedGoogle Scholar
• 12 Consensus Statement. EASL International Consensus Conference on Hepatitis C.  J Hepatol . 1999;  30 956-961
  CrossrefPubMedGoogle Scholar
• 13 Poynard T, Lebrec D. The inconvenience of investigations used in hepatology: patients' and hepatologists' opinions.  Liver . 1982;  2 369-375
  PubMedGoogle Scholar
• 13a Scheuer P J. Classification of chronic viral hepatitis: a need for reassessment.  J Hepatol . 1991;  13 372-374
  CrossrefPubMedGoogle Scholar
• 14 Ludwig J. The nomenclature of chronic active hepatitis: an obituary.  Gastroenterology . 1993;  105 274-278
  PubMedGoogle Scholar
• 15 Desmet V J, Gerber M, Hoofnagle J H, Manns M, Scheuer P J. Classification of chronic hepatitis: diagnosis, grading and staging.  Hepatology . 1994;  19 1513-1519
  CrossrefPubMedGoogle Scholar
• 16 Bedossa P, Poynard T, the METAVIR Cooperative Group. Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C.  Hepatology . 1994;  20 1:15-20
  PubMedGoogle Scholar
• 17 Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.  Hepatology . 1996;  24 289-293
  PubMedGoogle Scholar
• 18 Knodell K G, Ishak K G, Black W C. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.  Hepatology . 1981;  1 431-435
  CrossrefPubMedGoogle Scholar
• 19 Wong V S, Wight D G, Palmer C R, Alexander G J. Fibrosis and other histological features in chronic hepatitis C virus infection: a statistical model.  J Clin Pathol . 1996;  49 465-469
  PubMedGoogle Scholar
• 20 Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups.  J Viral Hepatol . 1997;  4 199-208
  CrossrefPubMedGoogle Scholar
• 21 Paradis V, Mathurin P, Laurent A. Histological features predictive of liver fibrosis in chronic hepatitis C infection.  J Clin Pathol . 1996;  49 998-1004
  PubMedGoogle Scholar
• 22 Yano M, Kumada H, Kage M. The long term pathological evolution of chronic hepatitis C.  Hepatology . 1996;  23 1334-1340
  CrossrefPubMedGoogle Scholar
• 23 Datz C, Cramp M, Haas T. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre.  Gut . 1999;  44 563-567
  CrossrefPubMedGoogle Scholar
• 24 Poynard T, McHutchison J, Davis G, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J, and the FIBROVIRC Project Group. Impact of interferon alfa-2b and ribavirin on the liver fibrosis progression in patients with chronic hepatitis C.  Hepatology . 1998;  28 497A
  PubMedGoogle Scholar
• 25 Wiley T E, McCarthy M, Breidi L, McCarthy M, Layden T J. Impact of alcohol on the histological and clinical progression of hepatitis C infection.  Hepatology . 1998;  28 805-809
  CrossrefPubMedGoogle Scholar
• 26 Benhamou Y, Bochet M, Di Martino V. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.  Hepatology . 1999;  30 1054-1058
  CrossrefPubMedGoogle Scholar
• 27 von Frerichs. Uber den diabetes Berlin: Hirschwald 1884
• 28 Schupfer F. De la possibilité de faire ``intra vitam'' un diagnostic précis des maladies du foie et de la rate.  Semin Méd . 1907;  27 229-230
  PubMedGoogle Scholar
• 29 Huard P. La ponction biopsie du foie et son utilité dans le diagnostic des affections hépatiques.  Ann Anat Path . 1935;  12 1118-1124
  PubMedGoogle Scholar
• 30 Theodossi A, Spiegelhalter D, Portmann B, Eddleston A L, Williams R. The value of clinical, biochemical, ultrasound and liver biopsy data in assessing patients with liver disease.  Liver . 1983;  3 315-326
  PubMedGoogle Scholar
• 31 Soloway R D, Baggenstoss A H, Schoenfield L J, Summerskill W H. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy.  Am J Dig Dis . 1971;  16 1082-1086
  PubMedGoogle Scholar
• 32 Theodossi A, Skene A M, Portmann B. Observer variation in assessment of liver biopsies including analysis by kappa statistics.  Gastroenterology . 1980;  79 232-241
  PubMedGoogle Scholar
• 33 Pagliaro L, Rinaldi F, Craxi A. Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial.  Dig Dis Sci . 1983;  28 39-43
  CrossrefPubMedGoogle Scholar
• 34 Colombo M, Del Ninno E, de Franchis R. Ultrasound-assisted percutaneous liver biopsy: superiority of the Tru-Cut over the Menghini needle for diagnosis of cirrhosis.  Gastroenterology . 1998;  95 487-489
  PubMedGoogle Scholar
• 35 Papini E, Pacella C M, Rossi Z. A randomized trial of ultrasound-guided anterior subcostal liver biopsy versus the conventional Menghini technique.  J Hepatol . 1991;  13 291-297
  PubMedGoogle Scholar
• 36 Lindor K D, Bru C, Jorgensen R A. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy.  Hepatology . 1996;  23 1079-1083
  CrossrefPubMedGoogle Scholar
• 37 Maharaj B, Maharaj R J, Leary W P. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver.  Lancet . 1986;  1 523-525
  PubMedGoogle Scholar
• 38 Crawford A R, Lin X Z, Crawford J M. The normal adult human liver biopsy: a quantitative reference standard.  Hepatology . 1998;  28 323-331
  CrossrefPubMedGoogle Scholar
• 39 Urena M A, Ruiz-Delgado F C, Gonzalez E M. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program.  Transplant Proc . 1998;  30 3288-3291
  CrossrefPubMedGoogle Scholar
• 40 Gayral F, Potier M, Salmon R, Labayle D, Larrieu H. Vascular complications of needle biopsy of the liver.  J Chir (Paris) . 1979;  116 261-264
  PubMedGoogle Scholar
• 41 Lebrec D, Goldfarb G, Degott C, Rueff B, Benhamou J P. Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure.  Gastroenterology . 1982;  83 338-340
  PubMedGoogle Scholar
• 42 Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies.  J Hepatol . 1986;  2 165-173
  CrossrefPubMedGoogle Scholar
• 43 McGill D B, Rakela J, Zinsmeister A R, Ott B J. A 21-year experience with major hemorrhage after percutaneous liver biopsy.  Gastroenterology . 1990;  99 1396-1400
  PubMedGoogle Scholar
• 44 Maharaj B, Bhoora I G. Complications associated with percutaneous needle biopsy of the liver when one, two or three specimens are taken.  Postgrad Med J . 1992;  68 964-967
  PubMedGoogle Scholar
• 45 Van Thiel H D, Gavaler J S, Wright H, Tzakis A. Liver biopsy. Its safety and complications as seen at a liver transplant center.  Transplantation . 1993;  55 1087-1090
  PubMedGoogle Scholar
• 46 Janes C H, Lindor K D. Outcome of patients hospitalized for complications after outpatient liver biopsy.  Ann Intern Med . 1993;  118 96-98
  CrossrefPubMedGoogle Scholar
• 47 Gilmore I T, Burroughs A, Murray-Lyon I M, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London.  Gut . 1995;  36 437-441
  CrossrefPubMedGoogle Scholar
• 48 Vivas S, Palacio M A, Rodriguez M, Lomo J, Cadenas F, Giganto F, Rodrigo L. Ambulatory liver biopsy: complications and evolution in 264 cases.  Rev Esp Enferm Dig . 1998;  90 175-182
  PubMedGoogle Scholar
• 49 Teare J P, Sherman D, Greenfield S M. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis.  Lancet . 1993;  342 895-898
  CrossrefPubMedGoogle Scholar
• 50 Oberti F, Valsesia E, Pilette C. Noninvasive diagnosis of hepatic fibrosis or cirrhosis.  Gastroenterology . 1997;  113 1609-1616
  CrossrefPubMedGoogle Scholar
• 51 Bonacini M, Hadi G, Govindarajan S, Lindsay K L. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection.  Am J Gastroenterol . 1997;  92 1302-1304
  PubMedGoogle Scholar
• 52 Gaiani S, Gramantieri L, Venturoli N. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis?.  <~>A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol . 1997;  27 979-985
  CrossrefPubMedGoogle Scholar
• 53 Aube C, Oberti F, Korali N. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis.  J Hepatol . 1999;  30 472-478
  CrossrefPubMedGoogle Scholar
• 54 Mathurin P, Moussalli J, Cadranel J F. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.  Hepatology . 1998;  27 868-872
  CrossrefPubMedGoogle Scholar
• 55 Shiffman M L, Hofmann C M, Contos M J, Luketic V A, Sanyal A J, Sterling R K, Ferreira-Gonzalez A, Mills A S, Garret C. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.  Gastroenterology . 1999;  117 1164-1172
  CrossrefPubMedGoogle Scholar
• 56 Poynard T, Leroy V, Cohard M. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration.  Hepatology . 1996;  24 778-789
  PubMedGoogle Scholar
• 57 Camma C, Giunta M, Linea C, Pagliaro L. The effect of interferon in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis.  J Hepatol . 1997;  26 1187-1199
  CrossrefPubMedGoogle Scholar
• 58 Capra F, Casaril M, Gabrielli G B. Dolci Alpha-interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers.  J Hepatol . 1993;  18 112-118
  CrossrefPubMedGoogle Scholar
• 59 Fukuda Y, Nakano I, Katano Y. Assessment and treatment of liver disease in Japanese haemophilia patients.  Haemophilia . 1998;  4 595-600
  CrossrefPubMedGoogle Scholar
• 60 Kaplanski G, Farnarier C, Payan M J, Bongrand P, Durand J M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis.  Dig Dis Sci . 1997;  42 2277-2284
  CrossrefPubMedGoogle Scholar
• 61 Kasahara A, Hayashi N, Mochizuki K. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.  J Hepatol . 1997;  26 574-583
  CrossrefPubMedGoogle Scholar
• 62 Mazzoran L, Tamaro G, Mangiarotti M A. Effects of interferon therapy on fibrosis serum markers in HCV-positive chronic liver disease.  Eur J Gastroenterol Hepatol . 1998;  10 125-131
  PubMedGoogle Scholar
• 63 Napoli J, Bishop G A, McGuinness P H, Painter D M, McCaughan G W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines.  Hepatology . 1996;  24 759-765
  PubMedGoogle Scholar
• 64 Verbaan H, Bondeson L, Eriksson S. Non-invasive assessment of inflammatory activity and fibrosis (grade and stage) in chronic hepatitis C infection.  Scand J Gastroenterol . 1997;  32 494-499
  PubMedGoogle Scholar
• 65 Wong V S, Hughes V, Trull A, Wight D G, Petrik J, Alexander G J. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection.  J Viral Hepatol . 1998;  5 187-192
  CrossrefPubMedGoogle Scholar
• 66 Yamada M, Fukuda Y, Koyama Y. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C.  J Gastroenterol Hepatol . 1996;  11 646-651
  PubMedGoogle Scholar
• 67 Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu J, Hayakawa T. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease.  Acta Haematol . 1998;  99 212-216
  CrossrefPubMedGoogle Scholar